Buy FEMARA 5mg – PARA PHARMA Online

Description

Chemical name: 4-[(4-cyanophenyl)-(1,2,4-triazol-1-yl)methyl]benzonitrile;
Formula: C17H11N5
Anabolic activity index: not a steroid
Androgenic activity index: not a steroid

FEMARA 5mg – PARA PHARMA

1. Active Substance:

• Letrozole: Femara 5mg contains letrozole as its active pharmaceutical ingredient. Letrozole belongs to a class of medications known as aromatase inhibitors. It works by reducing the production of estrogen in the body, which can help inhibit the growth of hormone receptor-positive breast cancer.

2. Indications:

• Breast Cancer: Femara 5mg is indicated for the treatment of hormone receptor-positive breast cancer in postmenopausal women. It may be used as adjuvant therapy following surgery or as first-line or second-line treatment in advanced or metastatic breast cancer.

3. Dosage and Administration:

• The recommended dosage of Femara 5mg for breast cancer treatment is usually one tablet (5 mg) taken orally once daily.
• Tablets should be swallowed whole with a glass of water, with or without food.
• Treatment duration and dosage may vary depending on individual patient factors such as disease stage, response to treatment, and tolerability.

4. Effectiveness:

• Femara 5mg has been shown to be effective in reducing the risk of breast cancer recurrence and improving overall survival in postmenopausal women with hormone receptor-positive breast cancer.
• Clinical studies have demonstrated improvements in disease-free survival and time to progression in patients treated with letrozole compared to placebo or other hormonal therapies.

5. Safety Profile:

• Femara 5mg is generally well-tolerated when used as prescribed. Common side effects may include hot flashes, night sweats, fatigue, headache, and joint pain.
• Serious side effects such as bone fractures, osteoporosis, and cardiovascular events may occur but are rare.
• Patients should be monitored regularly for signs of adverse reactions, including changes in bone density, lipid profiles, and liver function tests.

6. Contraindications:

• Femara 5mg is contraindicated in premenopausal women, pregnant or breastfeeding women, and individuals with a known hypersensitivity to letrozole or any of the excipients in the formulation.
• It should not be used in patients with severe renal impairment or hepatic dysfunction.

7. Precautions:

• Femara 5mg should be used with caution in patients with a history of osteoporosis, cardiovascular disease, or thromboembolic disorders.
• It should be avoided in patients with a predisposition to estrogen-dependent tumors or those receiving concomitant estrogen-containing therapies.
• Patients should be advised to undergo regular bone density assessments and to adopt lifestyle modifications to reduce the risk of bone loss and fractures.

8. Storage:

• Femara 5mg tablets should be stored at room temperature (15°C to 30°C) in a dry place, away from moisture and heat.
• Keep the medication out of reach of children and pets.

Femara 5mg tablets, containing letrozole as the active ingredient, offer an effective treatment option for postmenopausal women with hormone receptor-positive breast cancer. Treatment should be initiated and supervised by a qualified healthcare professional, and patients should be closely monitored for both efficacy and safety throughout the treatment course.